DLL4 and pancreatic neoplasm: OMP-305B83 generated by this platform is a BsAb targeting Notch pathway ligand delta-like ligand 4 (DLL4) and VEGF, which is undergoing a phase 1a clinical study for patients with previously treated solid tumors (including ovarian cancer, endometrial cancer, breast cancer, and pancreatic cancer) (Table 1).